Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mannkind Corp (NQ: MNKD )

4.345 +0.115 (+2.72%)
Streaming Delayed Price Updated: 10:28 AM EDT, Apr 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 182,125
Open 4.280
Bid (Size) 4.340 (12)
Ask (Size) 4.350 (12)
Prev. Close 4.230
Today's Range 4.270 - 4.400
52wk Range 3.170 - 5.750
Shares Outstanding 264,305,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
MannKind Repays Certain Debt Obligations
From MannKind
Via GlobeNewswire

Performance

YTD
+10.84%
+10.84%
1 Month
+0.12%
+0.12%
3 Month
+23.44%
+23.44%
6 Month
+4.45%
+4.45%
1 Year
+9.72%
+9.72%

More News

Read More
MannKind Announces CFO Transition
From MannKind
Via GlobeNewswire
Earnings Scheduled For February 27, 2024
Via Benzinga
MannKind Earnings Preview
Via Benzinga
A Preview Of MannKind's Earnings
Via Benzinga
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Exposures Product Safety
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With MannKind Stock?
Via Benzinga
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
From MannKind
Via GlobeNewswire
Cramer Says Sprout Social Is In A 'Hot Spot,' But This Energy Stock Is 'Too Down And Out'
Via Benzinga
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
From MannKind
Via GlobeNewswire
MannKind Corporation Announces Participation at Upcoming Conferences
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
From MannKind
Via GlobeNewswire
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
From MannKind
Via GlobeNewswire
3 Biotech Stocks to Sell in January Before They Crash and Burn
Via InvestorPlace
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
From MannKind
Via GlobeNewswire
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
From MannKind
Via GlobeNewswire
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
High-Yield Haven: 3 Dividend Stocks to Secure Now
Via InvestorPlace
MannKind (MNKD) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
MannKind Corporation Reports 2023 Third Quarter Financial Results
From MannKind
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.